Oct 22 (Reuters) – Vicore Pharma Holding AB: * VICORE PHARMA HOLDING AB: PHASE 2B ASPIRE TRIAL OF BULOXIBUTID IN IPF PASSES PRE-PLANNED FUTILITY ANALYSIS, ON TRACK FOR MID-2027 TOPLINE RESULTS *
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
BRIEF-REA Group Sees New Buy Listings Down Low Single Digits In FY27
Oct 23 (Reuters) - REA Group Ltd: * SEES NEW BUY LISTINGS DOWN LOW SINGLE…
Elon Musk invests about $1 billion in Skydance, CNBC reports
Oct 22 (Reuters) - Elon Musk has made a roughly $1 billion investment in Skydance,…
Apple bets iPhone Duo can remake foldable market as sales begin
By Aditya Soni Oct 23 (Reuters) - For nearly two decades Apple has made only…
